Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Change in Account Payables (2020 - 2024)

Immuneering (IMRX) has 5 years of Change in Account Payables data on record, last reported at $56741.0 in Q4 2024.

  • For Q4 2024, Change in Account Payables fell 66.73% year-over-year to $56741.0; the TTM value through Dec 2024 reached -$112143.0, up 89.87%, while the annual FY2024 figure was -$112143.0, 89.87% up from the prior year.
  • Change in Account Payables reached $56741.0 in Q4 2024 per IMRX's latest filing, up from -$679454.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $1.1 million in Q3 2022 and bottomed at -$778202.0 in Q3 2023.
  • Average Change in Account Payables over 5 years is $55249.7, with a median of $90557.0 recorded in 2021.
  • Peak YoY movement for Change in Account Payables: plummeted 731.07% in 2022, then surged 675.42% in 2024.
  • A 5-year view of Change in Account Payables shows it stood at $274072.0 in 2020, then plummeted by 262.37% to -$445014.0 in 2021, then soared by 283.4% to $816177.0 in 2022, then tumbled by 79.1% to $170568.0 in 2023, then crashed by 66.73% to $56741.0 in 2024.
  • Per Business Quant database, its latest 3 readings for Change in Account Payables were $56741.0 in Q4 2024, -$679454.0 in Q3 2024, and $393177.0 in Q2 2024.